期刊文献+

奥曲肽治疗重症急性胰腺炎的应用研究

Octreotide for severe acute pancreatitis application
下载PDF
导出
摘要 目的探讨奥曲肽对重症急性胰腺炎(SAP)的临床治疗效果。方法 60例急性重症胰腺炎患者随机分为观察组和对照组各30例,对照组采用常规治疗方法,观察组在常规治疗基础上加用奥曲肽持续静脉滴注。比较2组疗效、症状改善时间和并发症发生情况。结果观察组患者白细胞、血淀粉酶、血糖恢复正常时间以及症状、体征消失时间均明显短于对照组(P<0.05),观察组并发症发生率亦明显低于对照组(P<0.05)。结论持续静脉滴注奥曲肽能有效治疗重症急性胰腺炎并减少并发症的发生,疗效显著,安全性高,值得临床推广应用。 Objective To explore clinical treatment effect of Octreotide on or severe acute pancreatitis(SAP).Methods 60 patients hospitalized with severe acute pancreatitis patients were randomly divided into the observation group and control group each 30 cases.The control treated with conventional therapy and the observation group in conventional treatment on the basis of add with Octreotide continuous intravenous drip.Compared with two groups curative effect,improvement of symptoms and complications.Results White blood cells,blood amylase,blood sugar resume normal time and abdominal pain relief,ascites disappear in the observation group patients were significantly better than that in the control group(P0.05).The complications in observation group was also significantly lower than which in control group(P0.05).Conclusion Continuous intravenous drip Octreotide is effect on severe acute pancreatitis with little complications,possesses ideal efficacy and safety.
出处 《基层医学论坛》 2012年第34期4500-4502,共3页 The Medical Forum
关键词 重症急性胰腺炎 奥曲肽 并发症 病死率 Severe acute pancreatitis Octreotide peptide Complications Fatality rate
  • 相关文献

参考文献4

二级参考文献7

  • 1vanOoijenB,TingaCJ,KortWJ,ZijlstraFJ,LambertsSW,WilsonJH.Effectsoflong-actingsomatostatinanalog(SMS201-995)oneicosanoidsynthesisandsurvivalinratswithacutenecrotizingpancreatitis.DigDisSci,1992,37:1434~1440.
  • 2KonturekPC,DembinskiA,WarzechaZ,IhlmA,CeranowiczP,KonturekSJ,StachuraJ,HahnEG.Comparisonofepidermalgrowthfactorandtransforminggrowthfactor-betaexpressioninhormone-inducedacutepancreatitisinrats.Digestion,1998,59:110~119.
  • 3KonturekPC,DembinskiA,WarzechaZ,CeranowiczP,KonturekSJ,StachuraJ,HahnEG.Expressionoftransforminggrowthfactor-beta1andepidermalgrowthfactorincaerulein-inducedpancreatitisinrat.JPhysiolPharmacol,1997,48:59~72.
  • 4WarzechaZ,DembinskiA,KonturekPC,CeranowiczP,KonturekSJ.Epidermalgrowthfactorprotectsagainstpancreaticdamageincaeruleininducedpancreatitis.Digestion,1999,60:314~323.
  • 5KobayashiK,KashimaK,HiguchiK,ArakawaT.[Themechanismsofgastrointestinalmucosalinjuryandrepair].NipponRinsho,1998,56:2215~2222.
  • 6SchenaFP.Roleofgrowthfactorsinacuterenalfailure.KidneyIntSuppl,1998,66:S11~S15.
  • 7IsfortRJ,CodyDB,StuardSB,RandallCJ,MillerC,RidderGM,DoersenCJ,RichardsWG,YoderBK,WilkinsonJE,WoychikRP.Thecombinationofepidermalgrowthfactorandtransforminggrowthfactor-betainducesnovelphenotypicchangesinmouseliverstemcelllines.JCellSci,1997,110(Pt24):3117~3129.

共引文献435

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部